The interesting session was Sunday 5/31. As Dr. Wicha has been involved in csc research for a long time his remarks were particularly interesting. Immunotherapies will need to be combined with csc therapies. His comments on the importance of FAK inhibitors position as a key mode. Not new , the addition of csc by some oncology drugs. A lot going on.